---
document_datetime: 2025-06-24 13:22:43
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imuldosa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: imuldosa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6566938
conversion_datetime: 2025-12-23 00:32:12.891383
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## IMULDOSA

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 23/06/2025                          |                                             | SmPC                             |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000272232                     | finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000274978 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information based on results from study CNTO1275CRD1003 (a phase 1, open- label, drug interaction study to evaluate the effect of ustekinumab on cytochrome P450 enzyme activities following induction and maintenance dosing in participants with active Crohn's disease or ulcerative colitis) and to update sections 4.8 and 5.1 to include patient exposure numbers based on results from study CNTO1275UCO3001 (a phase 3, randomised, double-blind, placebo- controlled, parallel-group, multicentre protocol to evaluate the safety and efficacy of ustekinumab induction and maintenance | 05/06/2025 | SmPC and PL | To update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information based on results from study CNTO1275CRD1003 and to update sections 4.8 and 5.1 to include patient exposure numbers based on results from study CNTO1275UCO3001. The PL is updated accordingly. The change follows assessment of the same change for the reference product Stelara. Additionally, the MAH took the opportunity to update the wording of the polysorbate warning in Section 2 of the PL, |

<div style=\"page-break-after: always\"></div>

|                                       | severely active ulcerative colitis). The PL is updated accordingly. The change follows assessment of the same change for the reference product Stelara. Additionally, the MAH took the opportunity to update the wording of the polysorbate warning in Section 2 of the PL, in line with the EC excipient guideline, and to implement minor editorial changes throughout the PI to align with the QRD template.   |            |      |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|
| Variation type IB / EMA/VR/0000266943 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                           | 03/06/2025 | SmPC |